Dr. MacDonald is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
2015 Uppergate Drive, 4th floor
Aflac Cancer & Blood Disorders Center
Atlanta, GA 30322Phone+1 404-727-4455Fax+1 404-727-4455
Summary
- Dr. Tobey MacDonald is a pediatric hematologist/oncologist in Atlanta, GA and is affiliated with multiple hospitals in the area, including Children's Healthcare of Atlanta, Emory University Hospital, and Children's Healthcare of Atlanta. He received his medical degree from Weill Cornell Medical College of Cornell University and has been in practice 26 years. He specializes in pediatric neuro-oncology.
Education & Training
- Children's Hospital Los AngelesFellowship, Pediatric Hematology/Oncology, 1994 - 1997
- Children's Hospital Los AngelesResidency, Pediatrics, 1991 - 1994
- Weill Cornell MedicineClass of 1991
- Cornell UniversityBA, Biology, 1983 - 1987
Certifications & Licensure
- CA State Medical License 1992 - Present
- GA State Medical License 2009 - 2025
- DC State Medical License 1998 - 2010
- VA State Medical License 1998 - 2010
- MD State Medical License 1998 - 2009
- American Board of Pediatrics Pediatric Hematology-Oncology
Awards, Honors, & Recognition
- Regional Top Doctor Castle Connolly, 2014
- Top Doctors- Pediatric Hematology Oncology US News & World Report
Clinical Trials
- Genetic Study of Newly Diagnosed Central Nervous System Tumors in Young Children Start of enrollment: 2001 Mar 01
- Cilengitide in Treating Children With Refractory Primary Brain Tumors Start of enrollment: 2003 Jul 01
- Molecularly Determined Treatment of Diffuse Intrinsic Pontine Gliomas (DIPG) Start of enrollment: 2011 Sep 01
- Join now to see all
Publications & Presentations
PubMed
- Medulloblastoma Spatial Transcriptomics Reveals Tumor Microenvironment Heterogeneity with High-Density Progenitor Cell Regions Correlating with High-Risk Disease.Franklin Chien, Marina E Michaud, Mojtaba Bakhtiari, Chanel Schroff, Matija Snuderl
Biorxiv. 2024-06-28 - 3 citationsSafety and pharmacokinetics of ONC201 (dordaviprone) administered two consecutive days per week in pediatric patients with H3 K27M-mutant glioma.Yazmin Odia, Carl Koschmann, Nicholas A Vitanza, Peter de Blank, Dolly Aguilera
Neuro-Oncology. 2024-05-03 - 7 citationsONC201 (Dordaviprone) in Recurrent H3 K27M-Mutant Diffuse Midline Glioma.Isabel Arrillaga-Romany, Sharon L Gardner, Yazmin Odia, Dolly Aguilera, Joshua E Allen
Journal of Clinical Oncology. 2024-05-01
Journal Articles
- White Matter Network Topology Relates to Cognitive Flexibility and Cumulative Neurological Risk in Adult Survivors of Pediatric Brain TumorsTobey MacDonald, MD, ScienceDirect
Press Mentions
- Georgia State University Researcher Awarded $3 Million to Study Brain Cancer SurvivorsDecember 8th, 2022
- Breaching the Blood-Brain Barrier to Deliver Precious PayloadsMay 7th, 2021
- Moleculin Announces Positive Interim Results in Pediatric Brain Tumor Phase 1 Clinical Trial at Emory UniversityOctober 1st, 2020
- Join now to see all
Grant Support
- The Role Of Pdgfr In Medulloblastoma ProgressionNational Cancer Institute2010
- The Role Of Pdgfr In Medulloblastoma ProgressionNational Cancer Institute2006–2009
- Phase II Study Of Bevacizumab PLUS Irinotecan (CAMPTORSAR) In Children With RecrNational Center For Research Resources2007–2008
- Pbtc 007 V10b- A Phase I/II Trial Of Zd 1839 (IRESSA)National Center For Research Resources2006–2008
- Pbtc016: A Phase I, Molecular Biology And Phase II Study Of Lapatinib (Gw5720aNational Center For Research Resources2006
- Pbtc-017: Phase I Study Of Cloretazine (VNP40101M) In Children With Recurrent,National Center For Research Resources2006
- Regulation- Medulloblastoma Growth By Alpha-V IntegrinsNational Cancer Institute2002–2006
- Phase I Trial Of SCH 66336 In Ped Patient W/ Refractory Or Recurrent Brain TumorNational Center For Research Resources2005
- Pbtc009 - Phase I Trial Of Gliadel And O6-BenzylguanineNational Center For Research Resources2005
- Pbtc-012: Phase I Study Of Cilengiude (Emd 121974) In Child W Brain TumorsNational Center For Research Resources2005
- Pbtc-006: A Phase I/II Trial Of STI571 In ChildrenNational Center For Research Resources2005
- Pbtc 005 - Phase I Trial Of Temozolomide &06 Benzylguanine In Pediatric PatientNational Center For Research Resources2005
- Pbtc 007 V1.0b- A Phase I/II Trial Of Zd 1839 (IRESSA)National Center For Research Resources2004
- Pbtc 005v1.1 Phase I Trial Of Temozolomide And O6-BenzylguanineNational Center For Research Resources2004
- Pbtc 003-A Phase I Trial Of Escalating Oral Dose Of SCH66336 In PediatricNational Center For Research Resources2004
- A Phase I Study Of Cilengitide (Emd 121974) In Pediatric Patients With RefractorNational Center For Research Resources2004
Professional Memberships
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: